These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25261563)

  • 1. Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye drops.
    Mäenpää J; Volotinen-Maja M; Kautiainen H; Neuvonen M; Niemi M; Neuvonen PJ; Backman JT
    Drug Metab Dispos; 2014 Dec; 42(12):2068-76. PubMed ID: 25261563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction.
    Edeki TI; He H; Wood AJ
    JAMA; 1995 Nov 22-29; 274(20):1611-3. PubMed ID: 7474246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers.
    Ruiz-Garcia A; Giri N; LaBadie RR; Ni G; Boutros T; Richie N; Kocinsky HS; Checchio TM; Bello CL
    J Clin Pharmacol; 2014 May; 54(5):555-62. PubMed ID: 24293056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac safety of ophthalmic timolol.
    Mäenpää J; Pelkonen O
    Expert Opin Drug Saf; 2016 Nov; 15(11):1549-1561. PubMed ID: 27534869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
    Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
    Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug interaction between cimetidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers.
    Ishii Y; Nakamura K; Tsutsumi K; Kotegawa T; Nakano S; Nakatsuka K
    J Clin Pharmacol; 2000 Feb; 40(2):193-9. PubMed ID: 10664926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.
    Segura M; Farré M; Pichini S; Peiró AM; Roset PN; Ramírez A; Ortuño J; Pacifici R; Zuccaro P; Segura J; de la Torre R
    Clin Pharmacokinet; 2005; 44(6):649-60. PubMed ID: 15910012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet.
    Kapil RP; Friedman K; Cipriano A; Michels G; Shet M; Mondal SA; Harris SC
    Clin Ther; 2015 Oct; 37(10):2286-96. PubMed ID: 26350273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study.
    Nieminen T; Uusitalo H; Mäenpää J; Turjanmaa V; Rane A; Lundgren S; Ropo A; Rontu R; Lehtimäki T; Kähönen M
    Eur J Clin Pharmacol; 2005 Dec; 61(11):811-9. PubMed ID: 16315032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of ophthalmic timolol: new aspects of an old drug.
    Volotinen M; Hakkola J; Pelkonen O; Vapaatalo H; Mäenpää J
    Basic Clin Pharmacol Toxicol; 2011 May; 108(5):297-303. PubMed ID: 21385322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers.
    Glue P; Winter H; Garbe K; Jakobi H; Lyudin A; Lenagh-Glue Z; Hung CT
    J Clin Pharmacol; 2015 Jun; 55(6):680-7. PubMed ID: 25651476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects.
    Nieminen T; Lehtimäki T; Mäenpää J; Ropo A; Uusitalo H; Kähönen M
    Scand J Clin Lab Invest; 2007; 67(2):237-45. PubMed ID: 17366003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects.
    Tsukada H; Chen YL; Xiao G; Lennek L; Milanovic SM; Worden M; Polhamus DG; Chiu YY; Hopkins SC; Galluppi GR
    Clin Pharmacokinet; 2023 Dec; 62(12):1755-1763. PubMed ID: 37882999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops.
    Korte JM; Kaila T; Saari KM
    Graefes Arch Clin Exp Ophthalmol; 2002 Jun; 240(6):430-5. PubMed ID: 12107508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.
    Troost J; Tatami S; Tsuda Y; Mattheus M; Mehlburger L; Wein M; Michel MC
    Br J Clin Pharmacol; 2011 Aug; 72(2):247-56. PubMed ID: 21496064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levels and systemic safety of 0.1% unpreserved timolol maleate gel, 0.5% timolol aqueous solution and 0.5% timolol maleate gel.
    Bonnin N; Nezzar H; Dubray C; Renault D; Olmiere C; Chiambaretta F
    J Fr Ophtalmol; 2012 Jan; 35(1):9-16. PubMed ID: 21992993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
    Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
    Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes.
    Jung EH; Lee YJ; Kim DH; Kang P; Lim CW; Cho CK; Jang CG; Lee SY; Bae JW
    Arch Pharm Res; 2020 Dec; 43(12):1356-1363. PubMed ID: 33245517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers.
    Schneider F; Stamler D; Bradbury MJ; Loupe PS; Gordon MF; Rabinovich-Guilatt L
    Eur J Clin Pharmacol; 2022 Jan; 78(1):11-18. PubMed ID: 34491372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.